Literature DB >> 15075623

Involvement of 5-HT1A receptors in behavioural effects of the cannabinoid receptor agonist CP 55,940 in male rats.

E M Marco1, L Pérez-Alvarez, E Borcel, M Rubio, C Guaza, E Ambrosio, S E File, M P Viveros.   

Abstract

We have studied the possible interaction between the cannabinoid receptor agonist CP 55,940 (1 and 50 microg/kg) and the 5-HT1A receptor antagonist WAY 100635 (1 mg/kg) in the modulation of plus-maze and holeboard activity in Wistar adult male rats. In the plus-maze, the higher dose of CP 55,940 induced an anxiogenic-like effect, whereas the lower dose induced anxiolytic-like responses. The 5-HT1A antagonist, which was silent in this test, attenuated the anxiogenic, but not the anxiolytic, effect of CP 55,940. In the holeboard, the higher dose of CP 55,940 significantly decreased head-dipping duration, and WAY 100635, which did not affect exploratory head-dipping when administered alone, antagonized this effect. The administration of WAY 100635 significantly increased grooming behaviour, and this effect was inhibited by the two doses of CP 55,940, which did not exert any effect, per se, on this parameter. We provide the first evidence implicating 5-HT1A receptors in anxiety-related behavioural responses to a cannabinoid agonist.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15075623     DOI: 10.1097/00008877-200402000-00003

Source DB:  PubMed          Journal:  Behav Pharmacol        ISSN: 0955-8810            Impact factor:   2.293


  35 in total

Review 1.  Cannabinoid-related agents in the treatment of anxiety disorders: current knowledge and future perspectives.

Authors:  Simone Tambaro; Marco Bortolato
Journal:  Recent Pat CNS Drug Discov       Date:  2012-04-01

2.  Alterations in behavioral flexibility by cannabinoid CB1 receptor agonists and antagonists.

Authors:  Matthew N Hill; Larissa M Froese; Anna C Morrish; Jane C Sun; Stan B Floresco
Journal:  Psychopharmacology (Berl)       Date:  2006-06-03       Impact factor: 4.530

Review 3.  Enhancement of endocannabinoid signaling and the pharmacotherapy of depression.

Authors:  Regina A Mangieri; Daniele Piomelli
Journal:  Pharmacol Res       Date:  2007-09-11       Impact factor: 7.658

Review 4.  The endocannabinoid system as a target for the treatment of cannabis dependence.

Authors:  Jason R Clapper; Regina A Mangieri; Daniele Piomelli
Journal:  Neuropharmacology       Date:  2008-07-19       Impact factor: 5.250

Review 5.  Substance use modulates stress reactivity: Behavioral and physiological outcomes.

Authors:  Anne Q Fosnocht; Lisa A Briand
Journal:  Physiol Behav       Date:  2016-02-19

6.  Anxiety does not contribute to social withdrawal in the subchronic phencyclidine rat model of schizophrenia.

Authors:  Alexandre Seillier; Andrea Giuffrida
Journal:  Behav Pharmacol       Date:  2017-10       Impact factor: 2.293

Review 7.  Anandamide and 2-arachidonoylglycerol: pharmacological properties, functional features, and emerging specificities of the two major endocannabinoids.

Authors:  Antonio Luchicchi; Marco Pistis
Journal:  Mol Neurobiol       Date:  2012-07-17       Impact factor: 5.590

8.  The serotonin1A receptor agonist 8-OHDPAT reverses delta 9-tetrahydrocannabinol-induced impairment of spatial memory and reduction of acetylcholine release in the dorsal hippocampus in rats.

Authors:  Keiichrio Inui; Nobuaki Egashira; Kenichi Mishima; Akiko Yano; Yoshiaki Matsumoto; Nobuyoshi Hasebe; Kohji Abe; Kazuhide Hayakawa; Tomoaki Ikeda; Katsunori Iwasaki; Michihiro Fujiwara
Journal:  Neurotox Res       Date:  2004       Impact factor: 3.911

9.  Chronic unpredictable stress enhances cocaine-conditioned place preference in type 1 cannabinoid receptor knockout mice.

Authors:  Laurence L Miller; Sara J Ward; Linda A Dykstra
Journal:  Behav Pharmacol       Date:  2008-09       Impact factor: 2.293

10.  Chronic treatment and withdrawal of the cannabinoid agonist WIN 55,212-2 modulate the sensitivity of presynaptic receptors involved in the regulation of monoamine syntheses in rat brain.

Authors:  David Moranta; Susana Esteban; Jesús A García-Sevilla
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-08-16       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.